

Your Abstract Submission Has Been Received

Print this page

You have submitted the following abstract to 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers. Receipt of this notice does not guarantee that your submission was complete or free of errors.

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-Naïve RMS Irrespective of Baseline Snfl Levels

Gabriel Pardo, MD, FAAN¹, Ludwig Kappos, MD^{2,3}, Anne H. Cross, MD⁴, Jens Kuhle, MD, PhD^{2,3}, Xavier Montalban, MD, PhD⁵, Natalia Khachanova, MD, PhD⁶, Alit Bhatt, MBBS⁷, Rebecca Piccolo, PhD⁸, Jing Xi, PhD⁹, Ibolya Boer, MD¹⁰, Douglas L. Arnold, MD^{11,12}, **Enrique Alvarez, MD, PhD¹³** and Tjalf Ziemssen, MD, PhD¹⁴, (1)Oklahoma Medical Research Foundation, Oklahoma City, OK, (2)Neurologic Clinic and Polyclinic and MS Center, Department of Head, Spine and Neuromedicine, University Hospital Basel, Basel, Switzerland, (3)Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland, (4)Department of Neurology, Washington University School of Medicine, St. Louis, MO, (5)Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia; (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain, (6)Pirogov Russian National Research Medical University, Moscow, Russian Federation, (7)Novartis Healthcare Pvt. Ltd., Hyderabad, India, (8)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (9)China Novartis Institutes For Biomedical Research Co., Ltd., Shanghai, China, (10)Novartis Pharma AG, Basel, Switzerland, (11)NeuroRx Research, Montreal, QC, Canada, (12)Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, (13)Department of Neurology, Rocky Mountain MS Center at the University of Colorado Anschutz Medical Center, University of Colorado, Aurora, CO, (14)Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany

Abstract Text:

Background: Data from the phase 3 ASCLEPIOS I/II trials (ofatumumab vs teriflunomide in people with relapsing multiple sclerosis [RMS]) demonstrated that baseline serum neurofilament light chain (sNfL) levels were prognostic for on-study lesion formation in the overall population, including a subgroup of recently diagnosed (within 3 years) treatment-naïve (RDTN) participants.

Objectives: To compare the efficacy of ofatumumab vs teriflunomide in reducing relapses and new/enlarging T2 (neT2) lesions in RDTN participants based on their baseline sNfL levels.

Methods: A baseline sNfL cutoff was predefined by the median sNfL value for the overall population across the ASCLEPIOS I/II trials; RDTN participants were stratified into high (\geq median [9.3 pg/mL]) and low ($<$ 9.3 pg/mL) sNfL categories. Adjusted annualized relapse rates (ARRs) and annualized neT2 lesion rates were assessed with ofatumumab vs teriflunomide in each sNfL category over the study duration (up to 30 months). The effect of treatment on the proportion of participants achieving no evidence of disease activity (NEDA-3) at Months 12 and 24 was also compared within each sNfL category.

Results: Across 576 RDTN participants with baseline sNfL available, ARR were reduced by 63.4% ($p=0.002$) and 37.2% ($p=0.119$) in the high and low sNfL categories, respectively, with ofatumumab vs teriflunomide. Ofatumumab reduced the annualized rate of neT2 lesions by 85.5% and 85.8% vs teriflunomide for high and low sNfL categories, respectively (both $p<0.001$). A higher proportion of participants achieved NEDA-3 status with ofatumumab vs teriflunomide treatment, regardless of baseline sNfL levels ($p<0.001$ in both sNfL groups at all time points).

Conclusions: Ofatumumab was consistently associated with reductions in clinical and radiological activity vs teriflunomide in RDTN participants regardless of their baseline sNfL levels. The results support the benefit of using high-efficacy therapies, such as ofatumumab, at an early stage in the MS disease course irrespective of sNfL levels.

Title:

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-Naïve RMS Irrespective of Baseline Snfl Levels

Submitter's E-mail Address:

molly.burke@envisionpharma.com

Preferred Presentation Format:

Poster

Category:

Disease-modifying therapy

Has this abstract been presented/published elsewhere prior to this meeting?:

No

Have you simultaneously submitted this abstract to another organization for consideration?:

Yes

Simultaneous submission details:

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 and the American Academy of Neurology (AAN) 2024. ACTRIMS Forum 2024 will be held Feb 29 - March 02, 2024 and AAN 2024 will be held April 13-18, 2024.

Would you give CMSC and International Journal of MS Care the first preference to any article that is submitted for publication based on this abstract presentation?:

No

Category: Disease-modifying therapy

Keywords:

Disease-modifying treatments in MS

First Author

Gabriel Pardo, MD, FAAN

Email: GABRIEL-PARDO@OMRF.ORG -- Will not be published

Oklahoma Medical Research Foundation
Oklahoma City OK
USA

Biographical Sketch Oklahoma City, OK, USA

[Click to view Conflict of Interest Disclosure](#)

Second Author

Ludwig Kappos, MD

Email: ludwig.kappos@usb.ch -- Will not be published

Neurologic Clinic and Policlinic and MS Center, Department of Head, Spine and
Neuromedicine, University Hospital Basel

Basel

Switzerland

Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments
of Biomedicine and Clinical Research, University Hospital and University of Basel

Basel

Switzerland

[Click to view Conflict of Interest Disclosure](#)

Third Author

Anne Cross, MD

Email: crossa@wustl.edu -- Will not be published

Department of Neurology, Washington University School of Medicine

St. Louis MO

USA

[Click to view Conflict of Interest Disclosure](#)

Fourth Author

Jens Kuhle, MD, PhD

Email: Jens.Kuhle@usb.ch -- Will not be published

Neurologic Clinic and Policlinic and MS Center, Department of Head, Spine and
Neuromedicine, University Hospital Basel

Basel

Switzerland

Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments
of Biomedicine and Clinical Research, University Hospital and University of Basel

Basel

Switzerland

[Click to view Conflict of Interest Disclosure](#)

Fifth Author

Xavier Montalban, MD, PhD

Email: xavier.montalban@cem-cat.org -- Will not be published

Alternate Email: xavier.montalban@vallhebron.cat -- Will not be published

Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia;
(Cemcat), Vall d'Hebron University Hospital
Barcelona
Spain

[Click to view Conflict of Interest Disclosure](#)

Sixth Author

Natalia Khachanova, MD, PhD

Email: voroba.nat@mail.ru -- Will not be published

Pirogov Russian National Research Medical University
Moscow
Russian Federation

[Click to view Conflict of Interest Disclosure](#)

Seventh Author

Alit Bhatt, MBBS

Email: alit.bhatt@novartis.com -- Will not be published

Novartis Healthcare Pvt. Ltd.
Hyderabad
India

[Click to view Conflict of Interest Disclosure](#)

Eighth Author

Rebecca Piccolo, PhD

Email: rebecca.piccolo@novartis.com -- Will not be published

Novartis Pharmaceuticals Corporation
East Hanover NJ
USA

[Click to view Conflict of Interest Disclosure](#)

Ninth Author

Jing Xi, PhD

Email: jing.xi@novartis.com -- Will not be published

China Novartis Institutes For Biomedical Research Co., Ltd.
Shanghai
China

[Click to view Conflict of Interest Disclosure](#)

Tenth Author

Ibolya Boer, MD

Email: ibolya.boer@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

[Click to view Conflict of Interest Disclosure](#)

Eleventh Author

Douglas Arnold, MD

Email: douglas.arnold@mcgill.ca -- Will not be published

NeuroRx Research
Montreal QC

Canada
Montreal Neurological Institute and Hospital, McGill University
Montreal QC
Canada

[Click to view Conflict of Interest Disclosure](#)

Twelfth Presenting Author

Presenting Author

Enrique Alvarez, MD, PhD
Email: enrique.alvarez@cuanschutz.edu -- Will not be published

Department of Neurology, Rocky Mountain MS Center at the University of Colorado
Anschutz Medical Center, University of Colorado
Aurora CO
USA

[Click to view Conflict of Interest Disclosure](#)

Thirteenth Author

Tjalf Ziemssen, MD, PhD
Email: Tjalf.Ziemssen@uniklinikum-dresden.de -- Will not be published

University Clinic Carl-Gustav Carus
Department of Neurology
Dresden
Germany

[Click to view Conflict of Interest Disclosure](#)

First Contact

Molly Burke, BA
Email: molly.burke@envisionpharma.com -- Will not be published
Alternate Email: EnvisionNovartisNeurology@envisionpharma.com -- Will not be published

Envision
Philadelphia PA

If necessary, you can make changes to your abstract submission.

To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to </cmsc/reminder.cgi> to have that URL mailed to you again. Your username/password are 9496/584626.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

[Tell us what you think of the abstract submission process](#)

[Home Page](#)